What Happened
- An analysis highlights how the combination of low government health spending and unregulated pricing in private corporate hospitals is placing severe financial strain on Indian patients across all income groups.
- India's public health expenditure, at approximately 1.84% of GDP in 2021-22, remains far below the National Health Policy (NHP) 2017 target of 2.5% of GDP, forcing patients to rely heavily on private care.
- Out-of-pocket expenditure (OOPE) — the share patients pay directly — was 47.1% of total health expenditure in 2021-22, down from 69.4% in 2004-05 but still among the highest rates in comparable middle-income countries.
- Corporate hospital chains exercise unchecked discretion over procedure pricing, diagnostic charges, and drug markups, with no standardised rate schedules mandated nationally.
- Regulatory mechanisms such as the Clinical Establishments (Registration and Regulation) Act, 2010 remain weakly implemented across most states, leaving the pricing gap largely unaddressed.
- The opacity in billing — combination of facility fees, professional fees, consumable charges, and pharmacy markups — makes it nearly impossible for patients to anticipate or contest costs.
Static Topic Bridges
Out-of-Pocket Expenditure (OOPE): India's Persistent Health Financing Challenge
Out-of-pocket expenditure refers to direct payments made by households at the time of receiving health services. High OOPE is strongly associated with catastrophic health expenditure (when health spending exceeds 10% of household income) and medical impoverishment (when health spending pushes households below the poverty line). India's OOPE remains structurally high because public spending has not kept pace with rising healthcare utilisation.
- India's OOPE as % of total health expenditure: 47.1% (2021-22) — still among the highest in Asia.
- 40–50% of OOPE is spent on medicines; 10% on diagnostic tests; 13% on doctor consultations.
- World Health Organization (WHO) benchmarks suggest OOPE above 15–20% of total health expenditure leads to severe financial risk for households.
- The WHO Global Health Expenditure Database shows India's total health expenditure was 3.83% of GDP in 2021-22, with government health expenditure at 1.84%.
- National Health Policy 2017 target: public health expenditure at 2.5% of GDP — not yet met by 2025.
- An estimated 55–60 million Indians are pushed into poverty annually due to healthcare costs.
Connection to this news: The persistently high OOPE is a direct consequence of insufficient public provision — patients who cannot access subsidised government hospitals (due to capacity constraints, quality concerns, or geography) must absorb private sector pricing with no regulatory protection.
Clinical Establishments Act, 2010: Regulatory Intent vs. Implementation Failure
The Clinical Establishments (Registration and Regulation) Act, 2010 is a central law that provides for mandatory registration and regulation of all clinical establishments (hospitals, nursing homes, clinics, pathology labs) across India. Section 12 of the Act empowers the National Council to prescribe minimum standards for services, including provisions that could be used to regulate pricing.
- As of 2025, only a handful of states (including Arunachal Pradesh, Himachal Pradesh, Mizoram, Sikkim, and Union Territories) have adopted the 2010 Act; major states like Maharashtra, Tamil Nadu, Karnataka, and West Bengal have their own state-level legislation or have not fully implemented the central law.
- The National Council for Clinical Establishments has issued standard treatment workflows but has not notified mandatory price schedules nationally.
- The Act does not currently mandate price transparency or disclosure of standard rates to patients before treatment.
- States like Delhi have attempted to cap prices at empanelled rates for some procedures under government health insurance schemes, but private patients outside these schemes remain unprotected.
- NHRC (National Human Rights Commission) has recommended enacting a strengthened National Clinical Establishments Regulation Act incorporating enforceable price ceilings and mandatory disclosure.
Connection to this news: The Clinical Establishments Act's poor adoption and the absence of price regulation provisions in most state implementations are central to why corporate hospitals can maintain opaque pricing. Strengthening this framework — through price schedules, mandatory billing transparency, or a national standard of care pricing — is the key policy lever.
Ayushman Bharat and the Limits of Insurance-Based Models
Ayushman Bharat — Pradhan Mantri Jan Arogya Yojana (PM-JAY), launched in 2018, is the world's largest government-funded health insurance scheme, providing health cover of Rs 5 lakh per family per year for approximately 55 crore beneficiaries (bottom 40% of the population by socio-economic criteria). However, insurance-based models alone cannot solve the OOPE problem if pricing for non-beneficiaries or non-covered procedures remains unregulated.
- PM-JAY operates on package rates for 1,949 defined procedures — private hospitals empanelled under the scheme must charge these capped rates for covered beneficiaries.
- Package rates are defined by the government and are often significantly lower than market rates, causing empanelled private hospitals to deliver services at low margins or selectively participate.
- Approximately 50 crore Indians (above the PM-JAY income threshold) have no equivalent price protection for private hospitalisation.
- The Insurance Regulatory and Development Authority of India (IRDAI) regulates private health insurance but does not regulate hospital pricing; it governs only the insurer-provider relationship.
- States like Tamil Nadu (Chief Minister's Comprehensive Health Insurance Scheme) and Andhra Pradesh (YSR Aarogyasri) have state-level schemes with different coverage populations and package rates.
Connection to this news: PM-JAY demonstrates that pricing regulation is administratively feasible — package rates exist and are implemented — but coverage is limited to a subset of the population and a defined list of procedures. Extending similar discipline to all patients across all procedures requires a fundamentally different regulatory approach.
Right to Health and Article 21 of the Constitution
The Supreme Court of India has consistently held that the right to health is an integral component of the right to life under Article 21 of the Constitution. Multiple landmark judgments have affirmed the state's positive obligation to ensure affordable healthcare.
- Paschim Banga Khet Mazdoor Samity v. State of West Bengal (1996): SC held that failure to provide emergency medical treatment violates Article 21.
- Consumer Education and Research Centre v. Union of India (1995): SC recognised the right to health as a fundamental right flowing from Article 21.
- The Directive Principles of State Policy (Article 47) explicitly direct the state to raise the level of nutrition and standard of living and to improve public health.
- The Constitution (124th Amendment) Bill does not yet create a standalone right to health, but judicial interpretation of Article 21 has effectively constitutionalised it.
- NHRC has invoked Article 21 in recommending enforceable healthcare pricing standards in the private sector.
Connection to this news: The constitutional framework provides the legal basis for the state to regulate private healthcare pricing. Judicial precedent and DPSP mandates together create a strong normative case for legislative intervention on price opacity in corporate hospitals.
Key Facts & Data
- India's OOPE as % of total health expenditure: 47.1% (2021-22); was 69.4% in 2004-05
- India's public health expenditure (2021-22): 1.84% of GDP (NHP 2017 target: 2.5%)
- Total health expenditure (2021-22): 3.83% of GDP (Rs 9,04,461 crore)
- Indians pushed into poverty by healthcare costs annually: estimated 55–60 million
- PM-JAY launched: September 23, 2018; covers bottom 40% (~55 crore beneficiaries)
- PM-JAY per family health cover: Rs 5 lakh per year
- PM-JAY defined procedures: 1,949 health benefit packages
- Clinical Establishments (Registration and Regulation) Act: enacted 2010
- OOPE component breakdown: ~40–50% medicines, ~10% diagnostics, ~13% consultations
- WHO threshold for safe OOPE: below 15–20% of total health expenditure
- Article 21 (Right to Life) consistently interpreted by SC to include right to health
- Article 47 DPSP: directive to improve public health and nutrition standards